HER2-Targeted Therapy for HER2 Low-Expressing Breast Cancer

Adam M. Brufsky, MD, PhD, FACP; Lee Schwartzberg, MD, FACP; Hope S. Rugo, MD; Francisco Esteva, MD, PhD; and Komal Jhaveri, MD, FACP, talk about the National Surgical Adjuvant Breast and Bowel Project B-47 trial that examined the value of adding trastuzumab to standard adjuvant chemotherapy in tumors expressing low levels of HER2 protein.